Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System

Acta Haematol. 2020;143(6):600-602. doi: 10.1159/000505605. Epub 2020 Mar 18.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism*
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • LIM Domain Proteins / metabolism*
  • Lymphoma, Large B-Cell, Diffuse* / diagnostic imaging
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / metabolism
  • Lymphoma, Large B-Cell, Diffuse* / mortality
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography*
  • Prednisone / administration & dosage
  • Proto-Oncogene Proteins / metabolism*
  • Rituximab / administration & dosage
  • Tumor Necrosis Factor Receptor Superfamily, Member 9 / metabolism*
  • Vincristine / administration & dosage

Substances

  • Adaptor Proteins, Signal Transducing
  • LIM Domain Proteins
  • LMO2 protein, human
  • Proto-Oncogene Proteins
  • R-CHOP protocol
  • TNFRSF9 protein, human
  • Tumor Necrosis Factor Receptor Superfamily, Member 9
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone